Wall Street Zen Upgrades Enlivex Therapeutics (NASDAQ:ENLV) to “Hold”

Enlivex Therapeutics (NASDAQ:ENLV) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

ENLV has been the topic of a number of other reports. Zacks Research raised Enlivex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 21st. Weiss Ratings reissued a “sell (d)” rating on shares of Enlivex Therapeutics in a research note on Friday, June 26th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $247.50.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ:ENLV opened at $1.35 on Friday. The stock has a market capitalization of $23.61 million, a P/E ratio of -0.16 and a beta of 1.60. The stock’s 50-day moving average price is $4.41 and its 200-day moving average price is $10.40. Enlivex Therapeutics has a 12-month low of $1.34 and a 12-month high of $27.15.

Institutional Trading of Enlivex Therapeutics

Several large investors have recently modified their holdings of the business. Renaissance Technologies LLC increased its holdings in Enlivex Therapeutics by 99.4% during the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after purchasing an additional 156,336 shares during the period. Susquehanna International Group LLP lifted its holdings in Enlivex Therapeutics by 1,428.5% in the 2nd quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after buying an additional 147,334 shares during the period. HRT Financial LP grew its position in shares of Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company’s stock worth $108,000 after buying an additional 135,198 shares during the last quarter. Bank of America Corp DE grew its position in shares of Enlivex Therapeutics by 53.2% in the 1st quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after buying an additional 45,303 shares during the last quarter. Finally, Jane Street Group LLC increased its stake in shares of Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares during the period. 1.02% of the stock is owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.